Study of coversin in patients with paroxysmal nocturnal hemoglobinuria
Phase of Trial: Phase III
Latest Information Update: 24 Apr 2017
At a glance
- Drugs Coversin (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions; Therapeutic Use
- 24 Apr 2017 According to Akari Therapeutics media release, the company is planning to initiate this phase III program in the fourth quarter of 2017 andanticipates initial data in first quarte of 2019.
- 27 Jan 2017 New trial record
- 03 Jan 2017 According to Akari Therapeutics media release, the company expects to begin this trial in the summer of 2017.